ARDS (Aridis Pharmaceuticals) Other Long-Term Liabilities: $-0.00 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals Other Long-Term Liabilities?

Aridis Pharmaceuticals ARDS 12 Other Long-Term Liabilities is $-0.00 Mil as of Sep. 2023. GuruFocus rates ARDS with a GF Score™ of 12/100.

Aridis Pharmaceuticals's other long-term liabilities for the quarter that ended in Sep. 2023 was $-0.00 Mil.

Aridis Pharmaceuticals's quarterly other long-term liabilities declined from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) and declined from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($-0.00 Mil).

Aridis Pharmaceuticals's annual other long-term liabilities increased from Dec. 2020 ($0.23 Mil) to Dec. 2021 ($0.36 Mil) but then declined from Dec. 2021 ($0.36 Mil) to Dec. 2022 ($-0.00 Mil).

Aridis Pharmaceuticals Other Long-Term Liabilities Related Terms

Aridis Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Aridis Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Other Long-Term Liabilities Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.23 0.36 -0.00

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 -0.00
ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Aridis Pharmaceuticals (ARDS) has a Other Long-Term Liabilities of $-0.00 Mil as of Sep. 2023. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' Other Long-Term Liabilities too high?
Aridis Pharmaceuticals' current Other Long-Term Liabilities is $-0.00 Mil. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Other Long-Term Liabilities compare to ARTL and REVB?
Aridis Pharmaceuticals' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aridis Pharmaceuticals and its competitors. Aridis Pharmaceuticals's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Other Long-Term Liabilities is $-0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price